Linked Life Data

12548594

Source:http://linkedlifedata.com/resource/pubmed/id/12548594

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2003-1-27
pubmed:abstractText
The similarity between the mechanism of action between docetaxel and estramustine generated the hypothesis of synergistic antimicrotubule effects and cytotoxicity when the two agents are combined. In addition, it has been demonstrated that estramustine binds P-glycoprotein in vitro and, thus, may prevent the efflux of taxanes in tumors that over-express P-glycoprotein. To further evaluate the combinations clinical efficacy and safety, a trial was performed in heavily pretreated patients with metastatic breast carcinoma (MBC).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0008-543X
pubmed:author
pubmed:copyrightInfo
Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11082
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
97
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
537-44
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma.
pubmed:affiliation
Department of Medicine, Division of Medical Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University/New York Presbyterian Hospital, New York, New York, USA. tiersten@cancercenter.columbia.edu
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II